Cassandra Pingali, MPH, MS1; David Yankey, PhD1; Laurie D. Elam-Evans, PhD1; Lauri E. Markowitz, MD2; Charnetta L. Williams, MD1; Benjamin Fredua, MS1,3; Lucy A. McNamara, PhD4; Shannon Stokley, DrPH1; James A. Singleton, PhD1 (View author affiliations)
View suggested citation SummaryWhat is already known about this topic?
Tetanus, diphtheria, and acellular pertussis (Tdap), meningococcal conjugate (MenACWY), and human papillomavirus (HPV) vaccines are routinely recommended for adolescents.
What is added by this report?
In 2020, adolescent coverage with Tdap and the first dose of MenACWY remained high and continued to improve for HPV vaccines, with some disparities. Adolescents living outside a metropolitan statistical area (MSA) had lower vaccination coverage compared with adolescents living in MSA principal cities.
What are the implications for public health?
Results from the 2020 National Immunization Survey–Teen reflect adolescent vaccination coverage before the COVID-19 pandemic. Efforts to reach adolescents whose routine medical care has been affected by the pandemic are necessary to protect adolescents and communities from vaccine-preventable diseases and outbreaks.
Altmetric: Citations: Views:Views equals page views plus PDF downloads
The Advisory Committee on Immunization Practices (ACIP) recommends that adolescents aged 11–12 years routinely receive tetanus, diphtheria, and acellular pertussis (Tdap); meningococcal conjugate (MenACWY); and human papillomavirus (HPV) vaccines. Catch-up vaccination is recommended for hepatitis B (HepB); hepatitis A (HepA); measles, mumps, and rubella (MMR); and varicella (VAR) vaccines for adolescents whose childhood vaccinations are not current. Adolescents are also recommended to receive a booster dose of MenACWY vaccine at age 16 years, and shared clinical decision-making is recommended for the serogroup B meningococcal vaccine (MenB) for persons aged 16–23 years (1). To estimate coverage with recommended vaccines, CDC analyzed data from the 2020 National Immunization Survey–Teen (NIS-Teen) for 20,163 adolescents aged 13–17 years.* Coverage with ≥1 dose of HPV vaccine increased from 71.5% in 2019 to 75.1% in 2020. The percentage of adolescents who were up to date† with HPV vaccination (HPV UTD) increased from 54.2% in 2019 to 58.6% in 2020. Coverage with ≥1 dose of Tdap, ≥1 dose (and among adolescents aged 17 years, ≥2 doses) of MenACWY remained similar to coverage in 2019 (90.1%, 89.3%, and 54.4% respectively). Coverage increased for ≥2 doses of HepA among adolescents aged 13–17 years and ≥1 dose of MenB among adolescents aged 17 years. Adolescents living below the federal poverty level§ had higher HPV vaccination coverage than adolescents living at or above the poverty level. Adolescents living outside a metropolitan statistical area (MSA)¶ had lower coverage with ≥1 MenACWY and ≥1 HPV dose, and a lower proportion being HPV UTD than adolescents in MSA principal cities. In 2020, the COVID-19 pandemic disrupted routine immunization services. Results from the 2020 NIS-Teen reflect adolescent vaccination coverage before the COVID-19 pandemic. The 2020 NIS-Teen data could be used to assess the impact of the COVID-19 pandemic on catch-up vaccination but not on routine adolescent vaccination because adolescents included in the survey were aged ≥13 years, past the age when most routine adolescent vaccines are recommended, and most vaccinations occurred before March 2020. Continued efforts to reach adolescents whose routine medical care has been affected by the COVID-19 pandemic are necessary to protect persons and communities from vaccine-preventable diseases and outbreaks.
NIS-Teen is an annual random-digit–dialed telephone survey** that monitors vaccination coverage in adolescents aged 13–17 years in all 50 states, the District of Columbia, selected local areas, and some U.S. territories.†† Parents or guardians of eligible adolescents are interviewed to gather sociodemographic information about the household, and consent to contact the adolescent’s vaccination provider (or providers) is requested; if permission is granted, a questionnaire is mailed to the provider (or providers) to obtain the adolescent’s vaccination history. Vaccination coverage estimates are based on provider-reported immunization records and include any vaccines administered before the 2020 NIS-Teen interview date. This report provides vaccination coverage estimates for 20,163 adolescents aged 13–17 years.§§ The overall household response rate¶¶ was 20.7%; 45.2% of adolescents with completed interviews had adequate provider data. Data were weighted and analyzed to account for the complex survey design, and T-tests using Taylor-series variance estimates were used to assess vaccination coverage differences by survey year (2020 versus 2019) and between sociodemographic groups.*** P-values <0.05 were considered statistically significant. Analyses were conducted using SAS-callable SUDAAN (version 11; RTI International). This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.†††
National Vaccination CoverageIn 2020, HPV vaccination coverage (≥1 dose) among adolescents was 75.1%, and 58.6% were HPV UTD (Figure) (Table 1). Coverage with ≥1 dose of Tdap and MenACWY remained high and stable (90.1% and 89.3% respectively). Among adolescents aged 17 years, coverage with ≥2 doses of MenACWY was 54.4%, similar to 2019 (53.7%); coverage increased for ≥1 dose of Men B among adolescents aged 17 years and catchup vaccination with ≥2 doses of HepA among adolescents 13−17 years from 2019. Coverage surpassed 90% for ≥2 doses of MMR, ≥3 doses of HepB, and ≥1 and ≥2 doses of varicella vaccine among adolescents without a history of varicella disease.§§§
Vaccination Coverage by Selected CharacteristicsAmong adolescents living in non-MSA areas, vaccination coverage was lower compared with those living in MSA principal cities with ≥1 dose MenACWY (85.7% versus 90.2% [−4.5 percentage points]), ≥1 dose HPV (68.0% versus 77.8% [−9.8 percentage points]), and ≥2 doses HepA (76.2% versus 83.6% [−7.4 percentage points])], and being HPV UTD (49.2% versus 60.4% [−11.2 percentage points]) (Table 2). These MSA disparities persisted among adolescents at or above the poverty level but were not significant among those below the poverty level for HPV UTD status and ≥2 dose–HepA coverage. The coverage disparity in non-MSA areas compared with MSA principal cities among adolescents living at or above the poverty level were largest for HPV UTD status (46.0% versus 59.8% [−13.8 percentage points]), ≥1-dose HPV coverage (64.9% versus 76.2% [−11.3 percentage points], and ≥2-dose HepA coverage (74.4% versus 83.6% [−9.2 percentage points]). Coverage varied by jurisdiction (Supplementary Table, https://stacks.cdc.gov/view/cdc/109214), race and ethnicity,¶¶¶ and health insurance status.****
COVID-19 Pandemic Effects on HPV VaccinationThe COVID-19 pandemic was declared a national emergency on March 13, 2020. To evaluate the impact of the pandemic on HPV vaccination, CDC conducted two analyses comparing the 2019 and 2020 NIS-Teen samples. Historically, HPV vaccination coverage has been lower than coverage with most other routine vaccines, allowing for more catch-up vaccinations among adolescents aged 13–17 years. Most adolescents had initiated HPV vaccination before March 1 in both survey years (69.1% in 2019 and 73.6% in 2020). An additional 2.4% and 1.5% of adolescents initiated the series after this date in 2019 and 2020, respectively.
The second analysis evaluated adolescents in the 2020 NIS-Teen sample who had not received HPV vaccine before March 1 and whose parent or guardian was interviewed on or after that date. This cohort was compared with a similarly constructed cohort using 2019 NIS-Teen data. Cumulative daily HPV vaccination initiation estimates from March through December for these cohorts were calculated using the Kaplan-Meier method.†††† Among the 4,918 adolescents who had not received HPV vaccine as of March 1, 2019 (26.2% of the total sample), 452 (15.0%) initiated the series by mid-December 2019. Among the 4,527 adolescents who had not received HPV vaccine as of March 1, 2020, (22.5% of total sample), 282 (15.2%) initiated the series by mid-December 2020. HPV vaccination initiation in the 2020 cohort was lower than that in the 2019 cohort by April. The difference between the two cohorts was largest in August and September (4.9 percentage points lower in 2020 in both months) but narrowed in subsequent months and was no longer significant by end of November (Supplementary Figure, https://stacks.cdc.gov/view/cdc/109215).
DiscussionNIS-Teen 2020 data indicate that although ≥1 dose HPV coverage and HPV UTD status continue to increase, they remain lower than coverage with most other routinely recommended vaccines. Improvements in HPV vaccination coverage are crucial to lowering rates of HPV-attributable cancers in the United States. Coverage with ≥1 dose of Tdap and MenACWY vaccines remains high and stable, while coverage with ≥2 doses of MenACWY remains low, indicating the need for increased awareness of the importance of the booster dose.
Disparities in vaccination coverage by MSA and poverty level persist. Among adolescents living at or above the poverty level, those in non-MSAs had lower HPV UTD status and coverage with ≥2 doses of HepA than adolescents in MSA principal cities. Further investigation is needed to understand this disparity and more generally, the relationship between socioeconomic level, geographic location, barriers to vaccination such as vaccination access, and vaccine confidence. Persons living below the poverty level might have better access to the VFC program,§§§§ which provides vaccines to children whose parents or guardians otherwise might not be able to afford them. Adolescents living below the poverty level have previously been shown to have higher HPV vaccine coverage (2–4).
Although HPV vaccination continues to increase in the United States, and coverage for most other routine vaccinations remains high and stable, the COVID-19 pandemic threatens these achievements. An analysis of immunization information systems data from 10 U.S. jurisdictions during March–May 2020 compared with the same period in 2018 and 2019 identified a substantial decrease in the number of vaccine doses administered to children and adolescents in 2020. Increases in doses administered were noted during June–September 2020 but did not appear sufficient to offset the decline during March–May 2020 (5). Analysis of adolescents in the 2019 and 2020 NIS-Teen data who were aged ≥13 years and had not initiated HPV vaccination as of March 1 showed lower series initiation initially from April through the end of October in 2020 compared with 2019; however, initiation of the HPV series in 2019 and 2020 was similar by November–December. Although this is encouraging, the NIS-Teen data cannot yet be used to assess the potential impact of the pandemic on adolescents who were due to receive vaccinations at age 11–12 years. As adolescents aged 11–12 years who were due to receive routine vaccinations during the pandemic age into the NIS-Teen survey sample (13–17 years), the full impact of the COVID-19 pandemic can be assessed.
The findings in this report are subject to at least three limitations. First, the household response rate was 20.7%, and 45.2% of respondents had adequate provider data. Low survey response rates can increase potential biases if survey participants differ from nonrespondents (6). Second, bias in estimates might remain after adjustment for household and provider nonresponse and phoneless households. A recent survey error assessment indicated that NIS-Teen estimates might underestimate true coverage, with the largest underestimation for Tdap vaccine (−5.3 percentage points).¶¶¶¶ Little evidence exists of a change in survey accuracy between 2019 and 2020.***** Finally, opportunity is limited to assess the effect of the pandemic on routine coverage using 2020 NIS-Teen data; because many vaccines are recommended for children aged 11–12 years, most adolescents aged 13–17 years received their routine vaccinations before the pandemic started.
Health care providers should review patient vaccination records and administer any vaccines or doses that are due. Children and adolescents aged 12–17 years are also eligible (those aged 16–17 years as of December 11, 2020 and those aged 12–15 years as of May 10, 2021) for a COVID-19 vaccine, which may be administered with other vaccines at the same visit (7). Ensuring that routine vaccination is maintained and that adolescents catch up on any missed doses is essential to protecting persons and communities from vaccine-preventable diseases and outbreaks.
Corresponding author: Cassandra Pingali, ncu9@cdc.gov.
1Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC; 2Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, CDC; 3Leidos Health, Atlanta, Georgia; 4Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC.
ReferencesAbbreviations: ACIP = Advisory Committee on Immunization Practices; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; NIS-teen = National Immunization Survey–Teen; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up to date.
* ≥1 dose Tdap at age ≥10 years; ≥1 dose MenACWY or meningococcal-unknown type vaccine; ≥2 doses MenACWY or meningococcal-unknown type vaccine, calculated only among adolescents aged 17 years at time of interview. Does not include adolescents who received their first and only dose of MenACWY at age ≥16 years; HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV). The routine ACIP recommendation for HPV vaccination was made for females in 2006 and for males in 2011. Because HPV vaccination was recommended for males in 2011, coverage for all adolescents was not measured before that year; HPV UTD includes those with ≥3 doses, and those with 2 doses when the first HPV vaccine dose was initiated at age <15 years and at least 5 months minus 4 days elapsed between the first and second dose.
† NIS-Teen implemented a revised adequate provider data definition in 2014 and retrospectively applied the revised definition to 2013 data. Estimates using a revised definition might not be directly comparable.
§ NIS-Teen moved in 2018 to a single-sample frame.
¶ ACIP revised the recommended HPV vaccination schedule in late 2016. The schedule changed from a 3-dose to 2-dose series with appropriate spacing between receipt of the first and second dose for immunocompetent adolescents initiating the series before the 15th birthday. Three doses are still recommended for adolescents initiating the series at age ≥15 years. Because of the change in definition, the graph includes estimates for ≥3 doses of HPV during 2011–2015 and the HPV UTD estimate for 2016–2020. Because HPV vaccination was recommended for males in 2011, coverage for all adolescents was not measured before that year.
TABLE 1. Estimated vaccination coverage with selected vaccines and doses among adolescents aged 13–17* years, by age at interview — National Immunization Survey–Teen, United States, 2020 Vaccine Age at interview (yrs), % (95% CI)† Total, % (95% CI)† 13 14 15 16 17 2020 2019 (n = 4,276) (n = 4,173) (n = 3,998) (n = 4,028) (n = 3,688) (N = 20,163) (N = 18,788) Tdap§ ≥1 dose 88.9 (87.0–90.6) 89.4 (87.1–91.3) 90.7 (88.7–92.5) 90.4 (88.3–92.1) 91.1 (88.7–93.0) 90.1 (89.2–90.9) 90.2 (89.2–91.1) MenACWY¶ ≥1 dose 87.5 (85.3–89.4) 87.6 (85.0–89.8) 90.4 (88.6–92.0)** 89.1 (86.9–91.0) 92.3 (90.3–93.9)** 89.3 (88.4–90.2) 88.9 (88.0–89.8) ≥2 doses†† NA NA NA NA 54.4 (51.2–57.5) 54.4 (51.2–57.5) 53.7 (49.9–57.4) HPV§§ vaccine All adolescents ≥1 dose 69.4 (66.6–72.1) 72.3 (69.4–75.0) 77.6 (75.3–79.8)** 77.2 (74.7–79.6)** 79.0 (76.4–81.4)** 75.1 (73.9–76.2)¶¶ 71.5 (70.1–72.8) HPV UTD*** 45.6 (42.7–48.5) 56.0 (53.0–58.9)** 61.9 (58.9–64.7)** 65.5 (62.6–68.2)** 64.5 (61.5–67.4)** 58.6 (57.3–60.0)¶¶ 54.2 (52.7–55.8) Females ≥1 dose 71.3 (67.7–74.7) 72.9 (68.4–77.0) 78.1 (74.6–81.3)** 80.3 (76.3–83.8)** 83.5 (80.8–85.9)** 77.1 (75.4–78.7)¶¶ 73.2 (71.3–75.0) HPV UTD 48.4 (44.3–52.5) 57.2 (52.6–61.7)** 63.7 (59.4–67.8)** 68.5 (64.0–72.6)** 70.4 (66.6–73.9)** 61.4 (59.5–63.3)¶¶ 56.8 (54.6–59.0) Males ≥1 dose 67.5 (63.2–71.5) 71.7 (67.9–75.2) 77.1 (73.9–80.1)** 74.5 (71.1–77.6)** 74.8 (70.4–78.6)** 73.1 (71.5–74.8)¶¶ 69.8 (67.9–71.7) HPV UTD 42.7 (38.6–46.9) 54.8 (50.9–58.6)** 60.0 (56.1–63.9)** 62.8 (58.9–66.4)** 59.0 (54.4–63.5)** 56.0 (54.1–57.8)¶¶ 51.8 (49.7–53.9) MenB ≥1 dose††† NA NA NA NA 28.4 (25.5–31.5) 28.4 (25.5–31.5)¶¶ 21.8 (18.9–24.9) MMR ≥2 doses 92.5 (90.7–94.0) 92.1 (90.3–93.5) 92.5 (90.4–94.2) 93.2 (91.5–94.7) 91.6 (89.2–93.5) 92.4 (91.6–93.2) 91.9 (90.8–92.8) Hepatitis A vaccine ≥2 doses§§§ 86.5 (84.1–88.5) 84.9 (82.6–86.9) 81.5 (79.1–83.6)** 79.8 (77.5–81.8)** 77.7 (75.0–80.1)** 82.1 (81.1–83.1)¶¶ 77.1 (75.8–78.4) Hepatitis B vaccine ≥3 doses 91.8 (89.8–93.4) 93.5 (92.1–94.8) 92.5 (90.7–94.0) 93.6 (92.0–94.8) 91.4 (89.1–93.3) 92.6 (91.8–93.3) 91.6 (90.6–92.6) Varicella History of varicella¶¶¶ 6.8 (5.4–8.5) 6.9 (5.7–8.3) 8.7 (7.1–10.6) 7.6 (6.4–9.1) 12.0 (9.7–14.8)** 8.4 (7.6–9.2) 9.1 (8.4–9.9) No history of varicella disease ≥1 dose vaccine 96.2 (94.8–97.2) 95.9 (94.4–97.0) 95.3 (93.5–96.7) 95.3 (93.3–96.7) 95.2 (93.6–96.5) 95.6 (94.9–96.2) 95.2 (94.3–95.9) ≥2 doses vaccine 93.6 (92.0–95.0) 91.6 (89.6–93.2) 92.8 (90.6–94.5) 90.8 (88.3–92.9)** 90.5 (88.1–92.5)** 91.9 (91.0–92.7) 90.6 (89.5–91.7) History of varicella or received ≥2 doses varicella vaccine 94.1 (92.6–95.3) 92.1 (90.3–93.6) 93.4 (91.4–95.0) 91.5 (89.2–93.4) 91.6 (89.5–93.4)** 92.6 (91.7–93.3) 91.5 (90.4–92.4)Abbreviations: CI = confidence interval; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; MenB = serogroup B meningococcal vaccine; MMR = measles, mumps, and rubella vaccine; NA = not applicable; NIS-Teen = National Immunization Survey–Teen; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up to date.
* Adolescents (20,163) in the 2020 NIS-Teen were born during January 2002–January 2008.
† Estimates with 95% CI widths >20 might be unreliable.
§ Includes percentages receiving Tdap vaccine at age ≥10 years.
¶ Includes percentages receiving MenACWY or meningococcal-unknown type vaccine.
** Statistically significant difference (p<0.05) in estimated vaccination coverage by age: reference group was adolescents aged 13 years.
†† ≥2 doses of MenACWY or meningococcal-unknown type vaccine. Calculated only among adolescents who were aged 17 years at interview. Does not include adolescents who received 1 dose of MenACWY vaccine at age ≥16 years.
§§ HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV). For ≥1 HPV dose measure and HPV UTD measure, percentages are reported among females and males combined (20,163) and among females only (9,576) and among males only (10,587).
¶¶ Statistically significant difference (p<0.05) compared with 2019 NIS-Teen estimates.
*** HPV UTD includes those with ≥3 doses, and those with 2 doses when the first HPV vaccine dose was initiated before age 15 years and there was at least 5 months minus 4 days between the first and second dose. This update to the HPV recommendation occurred in December 2016.
††† ≥1 dose of MenB. Calculated only among adolescents who were aged 17 years at interview. Administered based on individual clinical decision.
§§§ In July 2020, ACIP revised recommendations for HepA vaccination to include catch-up vaccination for children and adolescents aged 2–18 years who have not previously received HepA vaccine at any age. https://www.cdc.gov/mmwr/volumes/69/rr/rr6905a1.htm?s_cid=rr6905a1
¶¶¶ By parent or guardian report or provider records.
Abbreviations: CI = confidence interval; HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; MMR = measles, mumps, and rubella vaccine; MSA = metropolitan statistical area; NIS-Teen = National Immunization Survey–Teen; Tdap = tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; UTD = up to date; VAR = varicella vaccine.
* Adolescents (20,163) in the 2020 NIS-Teen were born during January 2002–January 2008.
† MSA status was determined based on household-reported county of residence and was grouped into three categories: MSA principal city, MSA nonprincipal city, and non-MSA. MSA and principal city were as defined by the U.S. Census Bureau https://www.census.gov/programs-surveys/metro-micro.html). Non-MSA areas include urban populations not located within an MSA as well as completely rural areas.
§ Estimates with 95% CI widths >20 might not be reliable.
¶ Includes percentages receiving Tdap vaccine at age ≥10 years.
** Includes percentages receiving MenACWY and meningococcal-unknown type vaccine.
†† Statistically significant difference (p<0.05) in estimated vaccination coverage by metropolitan statistical area; referent group was adolescents living in MSA principal city areas.
§§ ≥2 doses of MenACWY or meningococcal-unknown type vaccine. Calculated only among adolescents who were aged 17 years at interview. Does not include adolescents who received 1 dose of MenACWY vaccine at age ≥16 years.
¶¶ HPV vaccine, nine-valent (9vHPV), quadrivalent (4vHPV), or bivalent (2vHPV) in females and males combined.
*** HPV UTD includes those with ≥3 doses, and those with 2 doses when the first HPV vaccine dose was initiated before age 15 years and there was at least 5 months minus 4 days between the first and second dose. This update to the HPV recommendation occurred in December 2016.
††† In July 2020, ACIP revised recommendations for HepA vaccination to include catch-up vaccination for children and adolescents aged 2–18 years who have not previously received HepA vaccine at any age. https://www.cdc.gov/mmwr/volumes/69/rr/rr6905a1.htm?s_cid=rr6905a1
§§§ By parent or guardian report or provider records.
Suggested citation for this article: Pingali C, Yankey D, Elam-Evans LD, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2020. MMWR Morb Mortal Wkly Rep 2021;70:1183–1190. DOI: http://dx.doi.org/10.15585/mmwr.mm7035a1.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3